NorthWest Academic Centre (J.J.K., C.D.S.), The University of Melbourne, St Albans, 3021, Victoria, Australia; Department of Ophthalmology (J.J.K.), Department of Surgery, The University of Melbourne, Heidelberg, 3081 Victoria, Australia; Orbital, Plastics and Lacrimal Unit (J.J.K.), The Royal Victorian Eye and Ear Hospital, East Melbourne, 3002 Victoria, Australia; School of Mathematics and Statistics (S.F.), University of Melbourne, Parkville, 3052 Victoria, Australia; Department of Ophthalmology (S.R., J.E.C.), Flinders University of South Australia, Flinders Medical Centre, Bedford Park, 5042 South Australia, Australia; South Australian Institute of Ophthalmology (D.S.), University of Adelaide, Adelaide, 5000 South Australia, Australia; and Department of Medicine (P.R.E.), School of Clinical Sciences, Monash University, Clayton, 3168 Victoria, Australia.
J Clin Endocrinol Metab. 2016 Jul;101(7):2711-20. doi: 10.1210/jc.2015-4294. Epub 2016 Apr 7.
Previous association studies suggest the development of Graves' orbitopathy (GO) is variably influenced by environmental risk factors.
To determine the risk factors and predict odds for developing GO in Graves' hyperthyroidism (GH).
Case-control study.
Multi-centre Australian Thyroid-associated Orbitopathy Research group consisting of tertiary endocrinology and ophthalmology outpatients and related private practices.
A total of 1042 participants with GH were designated as cases if they had GO (n = 604) and controls if they did not have GO (n = 438).
Primary outcome was GO risk factors and secondary outcome was dysthyroid optic neuropathy (DON) with the effects of risk factors measured by odds ratio (OR) using multiple logistic regression, adjusted for known risk factors and exploratory variables.
The odds of GO increased by 17% for each decade increase in the age of onset of GH (OR 1.17, confidence interval (CI): 1.06-1.29; P = .002) and by 7% for each year increase in the duration of GH (OR 1.07, CI: 1.05-1.10; P < .001). Smoking increased the odds for GO by 2.22 for current smoker and 2.07 for exsmoker (P < .001), compared with never smoking. The odds of GO are 86% less in Graves' patients using antithyroid medication than those not (OR 0.14, CI: 0.06-0.34; P < .001). Predictors for DON were older age, oculomotility restriction, strabismus, reduced palpebral aperture, and active GO.
This study identified increase age of onset, duration of GH, and smoking as risk factors for GO. Usage of antithyroid medication was negatively related to GO. Older patients with restricted ocular motility, strabismus, and active GO are at higher risk of DON and may benefit from early medical intervention.
先前的关联研究表明,格雷夫斯眼病(GO)的发展受到环境风险因素的不同影响。
确定格雷夫斯甲亢(GH)中 GO 发展的危险因素,并预测其发生的可能性。
病例对照研究。
多中心澳大利亚甲状腺相关眼病研究组,由三级内分泌科和眼科门诊及相关私人诊所组成。
共有 1042 名 GH 患者被指定为病例,如果他们患有 GO(n=604),则为对照组,如果他们没有 GO(n=438)。
主要结局是 GO 的危险因素,次要结局是甲状腺机能亢进性眼病(DON),危险因素的影响通过多元逻辑回归用比值比(OR)来衡量,同时调整了已知的危险因素和探索性变量。
GO 的发病几率随 GH 发病年龄每增加十年增加 17%(OR 1.17,95%置信区间(CI):1.06-1.29;P=0.002),随 GH 持续时间每年增加 7%(OR 1.07,CI:1.05-1.10;P<.001)。与从不吸烟相比,当前吸烟者和以前吸烟者的 GO 发病几率分别增加 2.22 倍和 2.07 倍(P<.001)。与未使用抗甲状腺药物的 Graves 患者相比,使用抗甲状腺药物的 Graves 患者发生 GO 的几率降低了 86%(OR 0.14,95%CI:0.06-0.34;P<.001)。DON 的预测因子为年龄较大、眼球运动受限、斜视、睑裂缩小和活动性 GO。
本研究确定了年龄较大、GH 持续时间较长和吸烟是 GO 的危险因素。使用抗甲状腺药物与 GO 呈负相关。年龄较大、眼球运动受限、斜视和活动性 GO 的患者发生 DON 的风险更高,可能受益于早期的医学干预。